EU GMP Annex 22: What Pharmaceutical Manufacturers Need to Know About AI in 2026

The European Medicines Agency is finalizing Annex 22 to the EU GMP Guidelines — the first regulatory framework specifically addressing the use of artificial intelligence in pharmaceutical manufacturing. For QA Directors, Qualified Persons, and VP Quality roles across Europe, this guidance is not optional reading.

What Is Annex 22?

Annex 22 establishes requirements for the use of AI and machine learning models in GMP-regulated manufacturing processes. It covers:

• Risk classification of AI systems based on their impact on product quality and patient safety
• Validation requirements for AI models used in critical process decisions
• Human oversight requirements — the “human-on-the-loop” mandate
• Data governance and training data traceability
• Change control procedures when AI models are updated
• Audit trail requirements for AI-assisted decisions

The core principle is clear: AI systems that influence Critical Process Parameters (CPPs) or Critical Quality Attributes (CQAs) must be validated, explainable, and subject to human oversight.

What This Means For Batch Manufacturing

For pharmaceutical manufacturers running tablet compression, API synthesis, sterile filling, or any GMP batch process, Annex 22 creates both obligations and opportunities.

Obligations

• Any AI system used to monitor or adjust process parameters must be validated under GAMP 5 Category 4 or 5
• AI decisions must be logged with full traceability — who decided what, when, based on what data, with what confidence
• Human approval must be documented for any AI-recommended change to a Critical Process Parameter
• Model versions must be controlled — you must know which model version was active during every batch

Opportunities

• Manufacturers who build validated AI monitoring now will have a significant compliance advantage as Annex 22 becomes enforceable
• Real-time AI monitoring can reduce deviation investigation costs (€14,000 per deviation on average) by catching issues before they become deviations
• Automated GMP-compliant batch records reduce documentation burden on QA teams by 60-80%

The Human-On-The-Loop Requirement

One of the most important clarifications in Annex 22 is the distinction between autonomous AI and human-on-the-loop AI.

Fully autonomous AI — systems that make and execute decisions without human review — are not permitted for critical GMP decisions. The EU AI Act classification of pharmaceutical manufacturing AI as high-risk reinforces this position.

Human-on-the-loop AI — systems where AI analyzes, recommends, and drafts decisions, but a qualified human reviews and approves before execution — is the compliant architecture. This is exactly how BatchCortex is designed.

What Annex 22 Requires From Your Software

If you are evaluating AI batch monitoring software, Annex 22 compliance requires:

1. Full audit trail — every AI recommendation logged with timestamp, model version, input data snapshot, confidence score, and rationale. ALCOA+ compliant.
2. Electronic signatures — QA and QP sign-off on AI-generated batch reports must meet 21 CFR Part 11 / Annex 11 requirements.
3. Model version control — every batch record must identify which AI model version was active. Model updates require change control documentation.
4. Human override capability — operators must be able to reject AI recommendations. The system must log rejections with the same rigor as acceptances.
5. Explainability — AI recommendations must include a human-readable rationale. Black-box outputs are not acceptable for GMP decision support.
6. Validated infrastructure — the hosting environment, data pipeline, and application must be validated under GAMP 5. Cloud deployments require documented supplier qualification.

How BatchCortex Is Built For Annex 22

BatchCortex was designed from the ground up with Annex 22 compliance as a core requirement, not an afterthought.

Every AI recommendation is logged with full traceability. Every batch report identifies the model version used. Every sign-off is an electronic signature with timestamp and user identity. Human approval is required before any parameter adjustment is executed. The system cannot make autonomous changes to Critical Process Parameters.

We are preparing our GAMP 5 validation package for Q2 2026, ahead of Annex 22 enforcement timelines.

What To Do Now

For pharmaceutical manufacturers in Europe, the steps are clear:

1. Audit your current batch monitoring process — identify where AI could reduce deviation risk
2. Evaluate AI monitoring software against the Annex 22 checklist above
3. Begin your Computer System Validation planning — CSV takes 3-6 months minimum
4. Engage your Qualified Person early — QP sign-off on the validation approach is critical

The manufacturers who start their Annex 22 compliance journey in 2026 will be ahead of the curve when enforcement begins. Those who wait will face compressed timelines and higher validation costs.

BatchCortex is a GMP batch monitoring platform built for EU Annex 22 compliance. If you are evaluating AI monitoring solutions for your manufacturing site, review our GMP AI compliance overview and visit the BatchCortex homepage for platform details. You can also join our waitlist or contact vilmer@batchcortex.com.